Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5137-5145

  Soualhine, Hafid ^a   Deghmane, Ala Eddine ^a   Sun, Jim ^a   Mak, Karen ^a   Talal, Amina ^a   Av Gay, Yossef ^a   Hmama, Zakaria ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CATHEPSIN S; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOBACTERIUM ANTIGEN; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CATHEPSIN; HLA D ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BIOENGINEERING; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; HYBRIDOMA; LYMPHOCYTE ACTIVATION; LYSOSOME; MACROPHAGE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETICS; HELPER CELL; IMMUNOLOGY; INTRACELLULAR FLUID; METABOLISM; MICROBIOLOGY; SECRETION; TUMOR CELL LINE;

ACYLTRANSFERASES; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CATHEPSINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HLA-D ANTIGENS; HUMANS; INTRACELLULAR FLUID; MACROPHAGES; MYCOBACTERIUM BOVIS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TUBERCULOSIS VACCINES;

EID: 38449091281     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5137     Document Type: Article

References (65)

1. Baumann, S., E. A. Nasser, and S. H. Kaufmann. 2006. Progress in tuberculosis vaccine development. Curr. Opin. Immunol. 18: 438-448.
2. Broekmans, J. F. 1991. Tuberculosis and HIV-infection in developing countries. Trop. Geogr. Med. 43: S13-S21.
3. Charles, M., and J. W. Pape. 2006. Tuberculosis and HIV: implications in the developing world. Curr. HIV AIDS Rep. 3: 139-144.
4. Hestvik, A. L., Z. Hmama, and Y. Av-Gay. 2005. Mycobacterial manipulation of the host cell. FEMS Microbiol. Rev. 29: 1041-1050.
5. Nguyen, L., and J. Pieters. 2005. The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages. Trends Cell. Biol. 15: 269-276.
6. Mdluli, K., and M. Spigelman. 2006. Novel targets for tuberculosis drug discovery. Curr. Opin. Pharmacol. 6: 459-467.
7. Young, D., and C. Dye. 2006. The development and impact of tuberculosis vaccines. Cell 124: 683-687.
8. Bannon, M. J. 1999. BCG and tuberculosis. Arch. Dis. Child. 80: 80-83.
9. Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3: 656-662.
10. Baily, G. V. 1980. Tuberculosis prevention trial, Madras. Indian J. Med. Res. 72(Suppl.): 1-74.
11. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. J. Am. Med. Assoc. 271: 698-702.
12. Via, L. E., D. Deretic, R. J. Ulmer, N. S. Hibler, L. A. Huber, and V. Deretic. 1997. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J. Biol. Chem. 272: 13326-13331.
13. Pieters, J. 2001. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect. 3: 249-255.
14. Roberts, E. A., J. Chua, G. B. Kyei, and V. Deretic. 2006. Higher order Rab programming in phagolysosome biogenesis. J. Cell Biol. 174: 923-929.
15. + T cells of mycobacteria growing in human macrophages. Science 260: 984-986.
16. Busch, R., and E. D. Mellins. 1996. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr. Opin. Immunol. 8: 51-58.
17. Zachgo, S., B. Dobberstein, and G. Griffiths. 1992. A block in degradation of MHC class II-associated invariant chain correlates with a reduction in transport from endosome carrier vesicles to the prelysosome compartment. J. Cell. Sci. 103(Pt. 3): 811-822.
18. Loss, G. E., Jr., and A. J. Sant. 1993. Invariant chain retains MHC class II molecules in the endocytic pathway. J. Immunol. 150: 3187-3197.
19. Sendide, K., A. E. Deghmane, J. M. Reyrat, A. Talal, and Z. Hmama. 2004. Mycobacterium bovis BCG urease attenuates major histocompatibility complex class II trafficking to the macrophage cell surface. Infect. Immun. 72: 4200-4209.
20. Sendide, K., A. E. Deghmane, D. Pechkovsky, Y. Av-Gay, A. Talal, and Z. Hmama. 2005. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J. Immunol. 175: 5324-5332.
21. Bania, J., E. Gatti, H. Lelouard, A. David, F. Cappello, E. Weber, V. Camosseto, and P. Pierre. 2003. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc. Natl. Acad. Sci. USA 100: 6664-6669.
22. Riese, R. J., P. R. Wolf, D. Bromme, L. R. Natkin, J. A. Villadangos, H. L. Ploegh, and Chapman, H. A. 1996. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4: 357-366.
23. Villadangos, J. A., R. J. Riese, C. Peters, H. A. Chapman, and H. L. Ploegh. 1997. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 186: 549-560.
24. Garbe, T. R., J. Barathi, S. Barnini, Y. Zhang, C. Abou-Zeid, D. Tang, R. Mukherjee, and D. B. Young. 1994. Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology 140(Pt. 1): 133-138.
25. Matsuo, K., R. Yamaguchi, A. Yamazaki, H. Tasaka, and T. Yamada. 1988. Cloning and expression of the Mycobacterium bovis BCG gene for extracellular α antigen. J. Bacteriol. 170: 3847-3854.
26. lyn and phosphatidylinositol 3-kinase in human monocyte. J. Immunol. 156: 1157-1165.
27. Sugano, E., H. Tomita, T. Abe, A. Yamashita, and M. Tamai. 2003. Comparative study of cathepsins D and S in rat IPE and RPE cells. Exp. Eye Res. 77: 203-209.
28. Gehring, A. J., R. E. Rojas, D. H. Canaday, D. L. Lakey, C. V. Harding, and W. H. Boom. 2003. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits γ interferon-regulated HLA-DR and FcγR1 on human macrophages through Toll-like receptor 2. Infect. Immun. 71: 4487-4497.
29. Gehring, A. J., K. M. Dobos, J. T. Belisle, C. V. Harding, and W. H. Boom. 2004. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. J. Immunol. 173: 2660-2668.
30. Denzin, L. K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184: 2153-2165.
31. Benaroch, P., M. Yilla, G. Raposo, K. Ito, K. Miwa, H. J. Geuze, and H. L. Ploegh. 1995. How MHC class II molecules reach the endocytic pathway. EMBO J. 14: 37-49.
32. Wiendl, H., A. Lautwein, M. Mitsdorffer, S. Krause, S. Erfurth, W. Wienhold, M. Morgalla, E. Weber, H. S. Overkleeft, H. Lochmuller, et al. 2003. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J. Neuroimmunol. 138: 132-143.
33. Walker, B., J. F. Lynas, M. A. Meighan, and D. Bromme. 2000. Evaluation of dipeptide α-keto-β-aldehydes as new inhibitors of cathepsin S. Biochem. Biophys. Res. Commun. 275: 401-405.
34. Canaday, D. H., A. Gehring, E. G. Leonard, B. Eilertson, J. R. Schreiber, C. V. Harding, and W. H. Boom. 2003. T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. J. Immunol. Methods 281: 129-142.
35. Flynn, J. L., and J. Chan. 2003. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr. Opin. Immunol. 15: 450-455.
36. Blander, J. M., and R. Medzhitov. 2006. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7: 1029-1035.
37. Singh, C. R., R. A. Moulton, L. Y. Armitige, A. Bidani, M. Snuggs, S. Dhandayuthapani, R. L. Hunter, and C. Jagannath. 2006. Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is dependent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D. J. Immunol. 177: 3250-3259.
38. Pieters, J. 2001. Evasion of host cell defense mechanisms by pathogenic bacteria. Curr. Opin. Immunol. 13: 37-44.
39. Hmama, Z., R. Gabathuler, W. A. Jefferies, G. de Jon, and N. E. Reiner. 1998. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J. Immunol. 161: 4882-4893.
40. Eissenberg, L. G., and W. E. Goldman. 1988. Fusion of lysosomes with phagosomes containing Histoplasma capsulatum: use of fluoresceinated dextran. Adv. Exp. Med. Biol. 239: 53-61.
41. Hmama, Z., K. Sendide, A. Talal, R. Garcia, K. Dobos, and N. E. Reiner. 2004. Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1α, 25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J. Cell. Sci. 117: 2131-2140.
42. Huynh, K. K., E. L. Eskelinen, C. C. Scott, A. Malevanets, P. Saftig, and S. Grinstein. 2007. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 26: 313-324.
43. Ferrari, G., H. Langen, M. Naito, and J. Pieters. 1999. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97: 435-447.
44. van Pinxteren, L. A., J. P. Cassidy, B. H. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30: 3689-3698.
45. Mogues, T., M. E. Goodrich, L. Ryan, R. LaCourse, and R. J. North. 2001. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193: 271-280.
46. Caruso, A. M., N. Serbina, E. Klein, K. Triebold, B. R. Bloom, and J. L. Flynn. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J. Immunol. 162: 5407-5416.
47. Stüve, O., S. Youssef, A. J. Slavin, C. L. King, J. C. Patarroyo, D. L. Hirschberg, W. J. Brickey, J. M. Soos, J. F. Piskurich, H. A. Chapman, and S. S. Zamvil. 2002. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J. Immunol. 169: 6720-6732.
48. Quraishi, O., and A. C. Storer. 2001. Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S: contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family. J. Biol. Chem. 276: 8118-8124.
49. Chapman, H. A., R. J. Riese, and G. P. Shi. 1997. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 59: 63-88.
50. Liu, W., and D. M. Spero. 2004. Cysteine protease cathepsin S as a key step in antigen presentation. Drug News Perspect. 17: 357-363.
51. Stober, C. B., D. A. Lammas, C. M. Li, D. S. Kumararatne, S. L. Lightman, and C. A. McArdle. 2001. ATP-mediated killing of Mycobacterium bovis bacille Calmette-Guerin within human macrophages is calcium dependent and associated with the acidification of mycobacteria-containing phagosomes. J. Immunol. 166: 6276-6286.
52. Stewart, G. R., J. Patel, B. D. Robertson, A. Rae, and D. B. Young. 2005. Mycobacterial mutants with defective control of phagosomal acidification. PLoS. Pathog. 1: 269-278.
53. Matsuo, K., R. Yamaguchi, A. Yamazaki, H. Tasaka, K. Terasaka, M. Totsuka, K. Kobayashi, H. Yukitake, and T. Yamada. 1990. Establishment of a foreign antigen secretion system in mycobacteria. Infect. Immun. 58: 4049-4054.
54. Hess, J., D. Miko, A. Catic, V. Lehmensiek, D. G. Russell, and S. H. Kaufmann. 1998. Mycobacterium bovis bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95: 5299-5304.
55. Yamada, H., S. Matsumoto, T. Matsumoto, T. Yamada, and U. Yamashita. 2000. Murine IL-2 secreting recombinant bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J. Urol. 164: 526-531.
56. Haley, J. L., D. G. Young, A. Alexandroff, K. James, and A. M. Jackson. 1999. Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology 96: 114-121.
57. Vergne, I., J. Chua, S. B. Singh, and V. Deretic. 2004. Cell biology of mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 20: 367-394.
58. Belisle, J. T., V. D. Vissa, T. Sievert, K. Takayama, P. J. Brennan, and G. S. Besra. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: 1420-1422.
59. Kirschke, H., A. J. Barrett, and N. D. Rawlings. 1995. Proteinases 1: lysosomal cysteine proteinases. Protein Prof. 2: 1581-1643.
60. Horwitz, M. A., and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71: 1672-1679.
61. Horwitz, M. A. 2005. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. 7: 947-954.
62. McShane, H., A. A. Pathan, C. R. Sander, N. P. Goonetilleke, H. A. Fletcher, and A. V. Hill. 2005. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85: 47-52.
63. Flynn, J. L. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis 84: 93-101.
64. Wayne, L. G. 1994. Cultivation of Mycobacterium tuberculosis for research purposes. In Tuberculosis: Pathogenesis, Protection, and Control. B. R. Bloom, ed. ASM Press, Washington, pp. 73-83.
65. Reyrat, J. M., G. Lopez-Ramirez, C. Ofredo, B. Gicquel, and N. Winter. 1996. Urease activity does not contribute dramatically to persistence of Mycobacterium bovis bacillus Calmette-Guerin. Infect. Immun. 64: 3934-3936.